Novartis AG announced its third-quarter earnings, with core EPS of $2.46, surpassing market estimates of $2.28. Core operating income reached $6.04 billion, exceeding the estimated $5.61 billion. Net sales were $14.52 billion, also higher than the estimated $14.46 billion. Core net income was $4.66 billion, above the estimated $4.34 billion. Among these, Cosentyx sales were $1.86 billion and Entresto sales were $1.17 billion, both exceeding market expectations.